9th IAS Conference on HIV Science (IAS 2017), Paris, France, 23-26 July 2017

项目摘要-在过去几年中取得了重大的科学进步，有助于改善艾滋病毒 预防和治疗成果和提高成本效益，但仍然存在重大挑战，这可能 破坏实现结束艾滋病这一公共健康威胁的全球目标：更好的治疗和疫苗 仍然是应对艾滋病毒/结核病流行的一项紧迫挑战。需要做更多的工作才能实现规模扩大和 优化高负担地区的治疗策略。在实现雄心勃勃的目标方面，全球挑战依然存在 在整个护理过程中。迫切需要具体的创新来改进艾滋病毒检测及其吸收 并在终身护理中成功留住个人。这在青少年群体中尤为明显。 国际会计准则2017将有助于应对艾滋病毒预防、治疗和护理方面的一些持续挑战 在一个将整合创新方法的科学计划中，例如积极应用前卫 基础科学和实施研究中的技术，以及作为桥梁主题的精确医学。 法国在艾滋病毒科学方面的关键作用和使科学迅速转化为政策的强烈政治意愿， 加上该国与非洲和亚洲国家的紧密联系，这将是科学 会议计划，将展示来自全球各地的最新科学，并讨论其翻译成各种 了解具体的流行病学和政策背景。 IAS 2017将于2017年7月23日至26日在巴黎举行，预计将有6000至7000名代表出席 来自120多个国家。《国际会计准则2017》的具体目标是： 1.加快基础科学和创新，开发新的预防、治疗和护理方案； 2.加强对缓解治疗和疫苗的研究； 3.加强艾滋病毒与包括结核病、病毒在内的混合感染之间的知识转移和分享 肝炎、疟疾和合并症； 4.加强实施科学研究议程，以应对各种主要障碍和挑战 艾滋病毒预防和治疗在各种流行情景中层出不穷； 5.探讨艾滋病毒与人权之间的联系。 科学计划将由四个轨道组成：基础科学；临床科学；预防科学； 实施科学。艾滋病毒治疗和癌症研究研讨会，进一步关注治疗 疫苗将与会议一起组织。贯穿各领域的问题将在全体会议上讨论。 也将科学轨道与社区和领导力观点联系起来的会谈；桥梁会议被削减 跨越至少两个轨道，为多学科对话提供机会。中国政府的参与 青年研究人员、基础科学家和非传染性疾病等相关领域的研究人员将 通过积极征集相关科学知识和提供具体的财政支持来加强这方面的工作。

Project Summary - Significant scientific advances were made in the last few years that contribute to better HIV prevention and treatment outcomes and increased cost-effectiveness but major challenges remain that could undermine the attainment of the global goal to end AIDS as a public health threat: Better treatment and vaccines remain an urgent challenge to address the HIV/TB epidemic. Much more is needed to effect scale up and optimize treatment strategies in high-burden regions. Globally challenges remain in reaching ambitious targets across the continuum of care. Concrete innovations are urgently needed to improve HIV testing and its uptake and to retain individuals successfully in life-long care. This is particularly evident in adolescent populations. IAS 2017 will contribute to addressing some of the continuing challenges in HIV prevention, treatment and care in a scientific program that will integrate innovative approaches, such as the active application of avant-garde technologies in basic science and implementation research, and precision medicine as a bridging theme. France’s key role in HIV science and the strong political will enabling a rapid translation of science into policy, along with the country’s strong links with countries in Africa and Asia, will be defining factors for a scientific conference program that will present latest science from across the globe and discuss its translation into a variety of specific epidemiological and policy contexts. IAS 2017, taking place in Paris on 23-26 July 2017, has an expected attendance of 6,000 to 7,000 delegates from more than 120 countries. The specific aims of IAS 2017 are to: 1. Accelerate basic science and innovation for the development of new prevention, treatment and care options; 2. Strengthen research towards remission off treatment and a vaccine; 3. Enhance knowledge transfer and sharing between HIV and co-infections, including tuberculosis, viral hepatitis, malaria, and co-morbidities; 4. Strengthen the implementation science research agenda to address key barriers and challenges across the HIV prevention and treatment cascades in a variety of epidemic scenarios; 5. Explore the links between HIV and human rights. The scientific program will consist of four tracks: Basic Science; Clinical Science; Prevention Science; Implementation Science. A symposium on HIV cure and cancer research with a further focus on therapeutic vaccines will be organized in conjunction with the conference. Cross-cutting aspects will be covered in plenary talks that also connect the scientific tracks with community and leadership perspectives; bridging sessions cut across at least two of the tracks to provide opportunities for multi-disciplinary dialogues. The participation of young researchers, basic scientists and researchers in related fields such as non-communicable diseases will be strengthened by active solicitation of relevant science and the provision of specific financial support.